This website is intended for UK healthcare professionals only Log in | Register

Tag Archives: ENHANCE

May 2008 Br J Cardiol 2008;15:123–30

News from the 57th annual scientific session of the American College of Cardiology

Terry McCormack

Abstract

ENHANCE controversy dominates meeting The controversial ENHANCE (Ezetimibe and Simvastatin in Hypercholesterolaemia Enhances Atherosclerosis Regression) trial of ezetimibe dominated the ACC meeting, with a special session held to discuss the results, which were simultaneously published in the New England Journal of Medicine. The 720-patient trial showed no benefit of ezetimibe when added to simvastatin 80 mg in slowing the progression of atherosclerosis in the carotid artery (as measured by intima media thickness (IMT) in patients with familial hypercholesterolemia (FH), despite the fact that there were significantly greater reductions in lo

| Full text

January 2008 Br J Cardiol 2008;15:7-11

ENHANCE study shows no benefit of ezetimibe

BJCardio editorial team

Abstract

The ENHANCE study compared two years of treatment with ezetimibe/simvastatin 10/80 mg versus simvastatin 80 mg alone in 720 FH patients. The primary end point was the mean change in the intima-media thickness (IMT) measured at three sites in the carotid arteries.  This showed no statistically significant difference between treatment groups, with the change from baseline being 0.0111 mm for the ezetimibe/simvastatin group versus 0.0058 mm for the simvastatin alone group (p=0.29). Key secondary imaging end points, cardiac events and adverse events were also not different between the two groups. Ezetimibe was, however, associated with a greater

| Full text
Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now